Emmessar Biotech & Nutrition Limited (BOM:524768)
23.16
-1.34 (-5.47%)
At close: Sep 25, 2026
BOM:524768 Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 116 | 118 | 152 | 148 | 124 | 137 | |
Market Cap Growth | -34.59% | -22.47% | 2.25% | 19.84% | -9.82% | 87.08% |
Enterprise Value | 42 | 46 | 85 | 90 | 78 | 94 |
Last Close Price | 23.16 | 23.56 | 30.39 | 29.72 | 24.80 | 27.50 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 31.49 | 27.02 | 48.03 | 19.81 | 24.59 | 28.90 |
PS Ratio | 4.87 | 5.82 | 7.11 | 7.27 | 4.93 | 7.75 |
PB Ratio | 1.43 | 1.45 | 1.97 | 2.01 | 1.86 | 2.23 |
P/TBV Ratio | 1.43 | 1.45 | 1.97 | 2.01 | 1.86 | 2.23 |
P/FCF Ratio | 45.08 | 45.85 | 67.81 | 23.04 | 35.41 | 7.00 |
P/OCF Ratio | 43.63 | 44.39 | 67.81 | 23.04 | 32.94 | 6.05 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 1.78 | 2.26 | 4.00 | 4.41 | 3.10 | 5.28 |
EV/EBITDA Ratio | 6.91 | 15.18 | 14.93 | 21.36 | 9.46 | 16.17 |
EV/EBIT Ratio | 8.26 | 22.76 | 18.01 | 27.80 | 10.67 | 19.23 |
EV/FCF Ratio | 16.53 | 17.79 | 38.10 | 13.97 | 22.29 | 4.76 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | - | - | - | 0.02 | 0.01 | - |
Debt / EBITDA Ratio | - | - | - | 0.26 | 0.10 | - |
Debt / FCF Ratio | - | - | - | 0.17 | 0.24 | - |
Net Debt / Equity Ratio | -0.90 | -0.90 | -0.89 | -0.82 | -0.77 | -0.74 |
Net Debt / EBITDA Ratio | -11.92 | -24.36 | -12.05 | -14.43 | -6.21 | -7.93 |
Net Debt / FCF Ratio | - | -28.54 | -30.73 | -9.43 | -14.63 | -2.34 |
Asset Turnover | - | 0.21 | 0.24 | 0.25 | 0.33 | 0.24 |
Inventory Turnover | - | 0.97 | 1.74 | 1.77 | 4.24 | 2.00 |
Quick Ratio | - | 11.95 | 10.68 | 12.33 | 12.64 | 14.30 |
Current Ratio | - | 12.68 | 11.34 | 13.56 | 14.15 | 14.73 |
Return on Equity (ROE) | - | 5.51% | 4.18% | 10.66% | 7.85% | 8.01% |
Return on Assets (ROA) | - | 1.31% | 3.26% | 2.43% | 6.03% | 4.05% |
Return on Invested Capital (ROIC) | 50.53% | 18.69% | 14.56% | 20.84% | 24.39% | 10.35% |
Return on Capital Employed (ROCE) | - | 2.20% | 5.40% | 3.90% | 9.70% | 7.10% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 3.42% | 3.70% | 2.08% | 5.05% | 4.07% | 3.46% |
FCF Yield | 2.22% | 2.18% | 1.47% | 4.34% | 2.82% | 14.30% |
Buyback Yield / Dilution | -3.50% | - | - | - | - | 0.00% |